Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

18.41 +0.33 (+1.83%)

Streaming Delayed Price Updated: 12:03 PM EDT, May 6, 2026 Add to My Watchlist

Price and Volume

Volume	40,107
Open	18.26
Bid (Size)	18.22 (100)
Ask (Size)	18.49 (500)
Prev. Close	18.08
Today's Range	17.53 - 18.57
52wk Range	8.720 - 27.41
Shares Outstanding	64,532,091
Dividend Yield	2.61%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Crescent Biopharma to Present at May Investor Conferences

Today 7:30 EDT

From Crescent Biopharma, Inc.

Via GlobeNewswire

Which stocks are moving on Friday? ↗

May 01, 2026

Via Chartmill

Performance

YTD	+66.2%	+66.2%
1 Month	-5.1%	-5.1%
3 Month	+87.5%	+87.5%
6 Month	+49.1%	+49.1%
1 Year	+16.6%	+16.6%

More News

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 01, 2026

Via Chartmill

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

April 29, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

April 24, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

March 27, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

March 06, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 26, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma to Present at March Investor Conferences

February 23, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

February 19, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

February 18, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 05, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

January 30, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

January 05, 2026

From Crescent Biopharma, Inc.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

December 18, 2025

From Crescent Biopharma, Inc.

Via GlobeNewswire

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today ↗

December 04, 2025

Via Stocktwits

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

December 04, 2025

From Crescent Biopharma, Inc.

Via GlobeNewswire

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

December 04, 2025

From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Via GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards

November 17, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 06, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present at November Investor Conferences

November 05, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

November 04, 2025

From Crescent Biopharma

Via GlobeNewswire

Crescent Biopharma to Present at September Investor Conferences

August 28, 2025

From Crescent Biopharma

Via GlobeNewswire

This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 25, 2025

Via Benzinga

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗

August 11, 2025

Via Benzinga

Frequently Asked Questions

Is Crescent Biopharma, Inc. - Common Stock publicly traded?

Yes, Crescent Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Crescent Biopharma, Inc. - Common Stock trade on?

Crescent Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Crescent Biopharma, Inc. - Common Stock?

The ticker symbol for Crescent Biopharma, Inc. - Common Stock is CBIO on the Nasdaq Stock Market

What is the current price of Crescent Biopharma, Inc. - Common Stock?

The current price of Crescent Biopharma, Inc. - Common Stock is 18.41

When was Crescent Biopharma, Inc. - Common Stock last traded?

The last trade of Crescent Biopharma, Inc. - Common Stock was at 05/06/26 12:03 PM ET

What is the market capitalization of Crescent Biopharma, Inc. - Common Stock?

The market capitalization of Crescent Biopharma, Inc. - Common Stock is 1.19B

How many shares of Crescent Biopharma, Inc. - Common Stock are outstanding?

Crescent Biopharma, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.